Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 8/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 8/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 10/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29910839 | 1.00 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1CHRM4OPRM1 | |
| SCHEMBL29943157 | 0.93 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1OPRM1BRD4 | |
| SCHEMBL30797027 | 0.93 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1OPRM1BRD4 | |
| SCHEMBL23301459 | 0.93 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1OPRM1BRD4 | |
| SCHEMBL29910593 | 0.90 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1CHRM4OPRM1 | |
| SCHEMBL23301401 | 0.90 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1CHRM4OPRM1 | |
| SCHEMBL29943546 | 0.89 | SMARCA2 (0.48) | SMARCA2SMARCA4PBRM1CHRM4BRD4 | |
| SCHEMBL23302058 | 0.85 | SMARCA2 (0.39) | SMARCA2SMARCA4PBRM1CHRM4TMEM97 | |
| SCHEMBL29910450 | 0.85 | SMARCA2 (0.39) | SMARCA2SMARCA4PBRM1CHRM4TMEM97 | |
| SCHEMBL23301307 | 0.85 | OPRM1 (0.43) | SMARCA2SMARCA4CHRM4OPRM1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | C4 THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | C4 THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-4054724-A1 | BIFUNCTIONAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-09-14 | — | — | EP | disclosed |
| WO-2021086785-A1 | BIFUNCTIONAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021083949-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | SMARCC1, SMARCC2, SMARCA2 | SMARCA2 3/4885SMARCA4 11/4885PBRM1 99/4885 |
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | ITCH, EGFR, MUC1 | SMARCA2 3260/4885SMARCA4 3599/4885PBRM1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.